WO2018117151A1 - 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその共結晶 - Google Patents
7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその共結晶 Download PDFInfo
- Publication number
- WO2018117151A1 WO2018117151A1 PCT/JP2017/045728 JP2017045728W WO2018117151A1 WO 2018117151 A1 WO2018117151 A1 WO 2018117151A1 JP 2017045728 W JP2017045728 W JP 2017045728W WO 2018117151 A1 WO2018117151 A1 WO 2018117151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- crystal
- added
- salt
- Prior art date
Links
- LOWWYYZBZNSPDT-ZBEGNZNMSA-N C[C@@H](C1)[C@](CC2)(CN2c2c(cc[nH]3)c3ncn2)N1C(CC#N)=O Chemical compound C[C@@H](C1)[C@](CC2)(CN2c2c(cc[nH]3)c3ncn2)N1C(CC#N)=O LOWWYYZBZNSPDT-ZBEGNZNMSA-N 0.000 description 4
- SDXAWLJRERMRKF-UHFFFAOYSA-N Cc1cc(C)n[nH]1 Chemical compound Cc1cc(C)n[nH]1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 2
- AAHDLRDOCKVUDL-NBFOIZRFSA-N C[C@@H]1C(C(OC(C)(C)C)=O)N(Cc2ccccc2)C1 Chemical compound C[C@@H]1C(C(OC(C)(C)C)=O)N(Cc2ccccc2)C1 AAHDLRDOCKVUDL-NBFOIZRFSA-N 0.000 description 1
- YOZQNFQINJKCQC-ZANVPECISA-N C[C@@H]1[C@](CC2)(CN2c2ncnc3c2cc[nH]3)NC1 Chemical compound C[C@@H]1[C@](CC2)(CN2c2ncnc3c2cc[nH]3)NC1 YOZQNFQINJKCQC-ZANVPECISA-N 0.000 description 1
- 0 C[C@]1C(*=O)NC1 Chemical compound C[C@]1C(*=O)NC1 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a method for producing a 7H-pyrrolo [2,3-d] pyrimidine derivative useful as a Janus kinase (JAK) inhibitor, its cocrystal, a method for producing the cocrystal, and 7H-pyrrolo [
- the present invention relates to a method for purifying a 2,3-d] pyrimidine derivative.
- JAK belongs to the cytoplasmic protein tyrosine kinase family and includes JAK1, JAK2, JAK3 and TYK2.
- Patent Document 1 discloses compound A (3-[(3S, 4R) -3-methyl-6- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1, useful as a JAK inhibitor. 6-diazaspiro [3.4] octane-1-yl] -3-oxopropanenitrile: also referred to herein as “compound [4]”.
- the present invention relates to a method for producing a 7H-pyrrolo [2,3-d] pyrimidine derivative useful as a JAK inhibitor, a cocrystal thereof, a method for producing the cocrystal, and 7H-pyrrolo [2,3- (3) using the cocrystal. d] A method for producing or purifying pyrimidine derivatives is provided.
- the present invention includes the following embodiments: 3-[(3S, 4R) -3-Methyl-6- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1,6-diazaspiro [3.4] octan-1-yl]- Co-crystal of 3-oxopropanenitrile and 3,5-dimethylpyrazole.
- FIG. 1 shows a differential scanning calorimetry (DSC) curve of a compound A (compound [4]) co-crystal with 3,5-dimethylpyrazole (molar ratio 2: 1) (compound [3-1]) seed crystal.
- FIG. 2 shows multiple recordings of powder X-ray diffraction patterns of compound A (compound [4]) co-crystal with 3,5-dimethylpyrazole (molar ratio 2: 1) (compound [3-1]) seed crystals. Show. The vertical axis represents the diffraction intensity (cps: counts per second), and the horizontal axis represents the diffraction angle 2 ⁇ (°).
- FIG. 1 shows a differential scanning calorimetry (DSC) curve of a compound A (compound [4]) co-crystal with 3,5-dimethylpyrazole (molar ratio 2: 1) (compound [3-1]) seed crystal.
- the vertical axis represents the diffraction intensity (cps: counts per second), and
- FIG. 3 shows a differential scanning calorimetry (DSC) curve of compound A (compound [4]) with 3,5-dimethylpyrazole co-crystal (molar ratio 2: 1) (compound [3-1]).
- FIG. 4 shows multiple recordings of the powder X-ray diffraction pattern of Compound A (Compound [4]) co-crystal with 3,5-dimethylpyrazole (molar ratio 2: 1) (Compound [3-1]).
- the vertical axis represents the diffraction intensity (cps: counts per second), and the horizontal axis represents the diffraction angle 2 ⁇ (°).
- FIG. 5 shows an ORTEP diagram of compound A (compound [4]) and 3,5-dimethylpyrazole co-crystal (molar ratio 2: 1) (compound [3-1]).
- the compound of formula [4] or a salt thereof is obtained from the co-crystal (for example, the compound [3a]) isolated in the above (1) or (2). be able to.
- a co-crystal (for example, compound [3a]) prepared in advance is added as a seed crystal to the reaction mixture, and then the compound of formula [4] is co-crystallized (for example, compound [3a]) from the reaction mixture.
- a crude product of the compound of the formula [4] or a salt thereof is added as a seed crystal to a co-crystal (for example, the compound [3a]) prepared in advance.
- Compound [3a] isolating the compound of formula [4] as a co-crystal (eg, compound [3a]).
- a purified compound of the formula [4] or a salt thereof can be obtained via
- a compound of the formula [4] may be described as a compound [4].
- the salt of the compound may be any salt formed with the compound according to the present invention.
- a salt with an inorganic acid a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, or an amino acid. Salt and the like are included.
- the inorganic acid include hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like.
- organic acids include oxalic acid, malonic acid, maleic acid, citric acid, fumaric acid, terephthalic acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methanesulfonic acid, Examples thereof include benzenesulfonic acid, p-toluenesulfonic acid, 10-camphorsulfonic acid and the like.
- the salt with an inorganic base include sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt and the like.
- organic base examples include methylamine, diethylamine, trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris (hydroxymethyl) methylamine, dicyclohexylamine, N, N-dibenzylethylenediamine, guanidine, pyridine, and picoline. , Choline, cinchonine, meglumine and the like.
- amino acids include lysine, arginine, aspartic acid, glutamic acid and the like.
- a salt of the compound of the present invention can be obtained by reacting the compound of the present invention with an inorganic base, organic base, inorganic acid, organic acid or amino acid.
- the compound according to the present invention or a salt thereof may exist as a solvate thereof.
- a solvate is a compound in which a solvent molecule is coordinated to a compound according to the present invention or a salt thereof, and includes a hydrate.
- the solvate is preferably a pharmaceutically acceptable solvate, for example, a hydrate, ethanol solvate, DMSO solvate, 1-propanol solvate, 2-propanol solvate of the compound according to the present invention or a salt thereof, Chloroform hydrate, dioxane solvate, anisole solvate, acetone solvate, ethylene glycol solvate, dimethylacetamide solvate and the like can be mentioned.
- a solvate of the compound according to the present invention or a salt thereof can be obtained.
- the compounds according to the present invention may exist as tautomers. In that case, the compounds according to the invention may exist as individual tautomers or as a mixture of different tautomers.
- the compound according to the present invention may have a carbon-carbon double bond. In that case, the compound according to the present invention may exist as E-form, Z-form, or a mixture of E-form and Z-form.
- the compounds according to the invention may exist as stereoisomers to be recognized as cis / trans isomers. In that case, the compound according to the present invention may exist as a cis form, a trans form, or a mixture of a cis form and a trans form.
- the compounds according to the invention may have one or more asymmetric carbon atoms.
- the compounds according to the invention may exist as a single enantiomer, a single diastereomer, a mixture of enantiomers or a mixture of diastereomers.
- the compounds according to the invention may exist as atropisomers. In that case, the compounds according to the invention may exist as individual atropisomers or as a mixture of different atropisomers.
- the compounds according to the invention may contain simultaneously a plurality of structural features giving rise to the isomers described above. In addition, the compound according to the present invention may contain the above isomers in any ratio.
- the formula, chemical structure, or compound name expressed without specifying stereochemistry can include all of the above-mentioned isomers that may exist, unless otherwise noted.
- the chemical bond indicated by the wavy line indicates that the compound is a mixture of stereoisomers or one of the isomers.
- the formula [10] The compound of the formula [10-1] and the formula [10-2] Or any one of the compounds.
- the diastereomer mixture can be separated into each diastereomer by a conventional method such as chromatography or crystallization.
- Each diastereomer can also be obtained by using a stereochemically single starting material or by a synthetic method using a stereoselective reaction.
- Separation of each enantiomer from the enantiomeric mixture can be accomplished by methods well known in the art. For example, fractional crystallization or chromatography from a mixture of diastereomers formed by reacting a mixture of enantiomers with a compound that is a substantially pure enantiomer known as a chiral auxiliary. Standard methods can be used to separate single diastereomers with increased isomer ratios or substantially pure. This separated diastereomer can be converted to the desired enantiomer by removing the added chiral auxiliary by a cleavage reaction.
- the desired enantiomer can also be obtained by directly separating the enantiomeric mixture by a chromatographic method using a chiral stationary phase well known in the art.
- the desired enantiomer can be synthesized by using a substantially pure optically active starting material, or by stereoselective synthesis using a chiral auxiliary or asymmetric catalyst for a prochiral synthetic intermediate (ie, It can also be obtained by carrying out (asymmetric induction).
- the absolute configuration can be determined by X-ray crystal structure analysis of the crystalline final product or synthetic intermediate. At that time, if necessary, the absolute configuration may be determined using a crystalline final product or synthetic intermediate derivatized with a reagent having an asymmetric center whose configuration is known. The configuration in this specification was specified based on the X-ray crystal structure analysis of the crystal of the chloroformate of Compound [4].
- the compound according to the present invention may be crystalline or amorphous.
- the compound according to the present invention may be labeled with an isotope element ( 3 H, 14 C, 35 S, etc.).
- m is an arbitrary number from 0.4 to 0.5.
- the co-crystal represented by is preferably a co-crystal having m of 0.5.
- m is 0.40 to 0.48, 0.40 to 0.46, 0.40 to 0.44, 0.40 to 0.42. 0.42 to 0.50, 0.44 to 0.50, 0.46 to 0.50, 0.48 to 0.50, 0.42 to 0.44, 0.44 to 0.46, or 0 A co-crystal of .46 to 0.48.
- the formula [4] The compound or a salt thereof is preferably a free form of the compound of the formula [4].
- the method for producing the co-crystal according to the present invention, or the compound according to the present invention or a salt thereof, or a solvate thereof is exemplified below.
- the reaction may be performed in a solvent.
- the compound obtained in each step can be isolated and purified by a known method such as distillation, recrystallization, column chromatography, etc., if necessary. In some cases, the next step is not isolated or purified. You can proceed to.
- room temperature indicates a state in which the temperature is not controlled, and in one embodiment means 1 ° C. to 40 ° C.
- the reaction temperature can comprise the stated temperature ⁇ 5 ° C., preferably ⁇ 2 ° C.
- a method for producing the co-crystal according to the present invention, or the compound according to the present invention or a salt thereof or a solvate thereof is exemplified in the following scheme. Specifically, a scheme via compound [3a] is shown. [In the scheme, m is an arbitrary number of 0.4 to 0.5. ]
- the co-crystal represented by the formula [3a] can be produced by condensing the compound of the formula [1] and 1-cyanoacetyl-3,5-dimethyl-1H-pyrazole (DPCN) [2].
- the compound of the formula [1] may be a salt thereof, and formation of a free form from a salt and a free form from a salt may be performed according to a known method.
- a preferred solvent is acetonitrile.
- DPCN [2] can be used, for example, in an amount of 0.95 equivalents to 1.2 equivalents, preferably 1.1 equivalents ⁇ 0.05 equivalents, relative to the compound of formula [1]. Another preferred embodiment is 1.0 equivalent ⁇ 0.05 equivalent.
- the reaction temperature is, for example, room temperature to 80 ° C., preferably 70 ° C. to 80 ° C.
- the reaction time is, for example, 0.5 hours to 12 hours, preferably 0.5 hours to 6 hours.
- the m of the co-crystal represented by the formula [3a] can be any number from 0.4 to 0.5 depending on the reaction conditions, the filtration conditions of the co-crystal, or the drying conditions.
- the co-crystal represented by formula [3a] has a diffraction angle (2 ⁇ ) measured using, for example, CuK ⁇ radiation of 4.6 ° ⁇ 0.2 °, 18.6 ° ⁇ 0.2 ° or 20.9 °.
- the co-crystal represented by formula [3a] has a diffraction angle (2 ⁇ ) measured using CuK ⁇ radiation of 4.6 ° ⁇ 0.1 °, 18.6 ° ⁇ 0.1 ° or 20.
- the co-crystal represented by the formula [3a] has a diffraction angle (2 ⁇ ) measured using, for example, CuK ⁇ radiation of 4.6 ° ⁇ 0.2 °, 12.6 ° ⁇ 0.2 °, 16. Powder having at least one peak (eg, at least 1, 2, 3, 4 or 5) at 1 ° ⁇ 0.2 °, 18.6 ° ⁇ 0.2 ° or 20.9 ° ⁇ 0.2 ° It is a crystal showing an X-ray diffraction pattern.
- the co-crystal represented by formula [3a] has a diffraction angle (2 ⁇ ) measured using CuK ⁇ radiation of 4.6 ° ⁇ 0.1 °, 12.6 ° ⁇ 0.1 °, 16.
- Powder having at least one peak (eg, at least 1, 2, 3, 4 or 5) at 1 ° ⁇ 0.1 °, 18.6 ° ⁇ 0.1 ° or 20.9 ° ⁇ 0.1 ° It is a crystal showing an X-ray diffraction pattern.
- the co-crystal represented by formula [3a] has a diffraction angle (2 ⁇ ) measured using CuK ⁇ radiation of 4.6 ° ⁇ 0.06 °, 12.6 ° ⁇ 0.06 °, 16 Has at least one peak (eg, at least 1, 2, 3, 4 or 5) at 1 ° ⁇ 0.06 °, 18.6 ° ⁇ 0.06 ° or 20.9 ° ⁇ 0.06 ° It is a crystal showing a powder X-ray diffraction pattern.
- the co-crystal represented by the formula [3a] is a co-crystal showing an extrapolation start temperature of 172 ⁇ 5 ° C. by differential scanning calorimetry.
- the co-crystal represented by the formula [3a] is a co-crystal that exhibits an extrapolated onset temperature of 172 ⁇ 3 ° C. by differential scanning calorimetry.
- the co-crystal represented by the formula [3a] is a co-crystal exhibiting an extrapolation start temperature of 172 ⁇ 1 ° C. by differential scanning calorimetry.
- the co-crystal represented by the formula [3a] is a co-crystal showing an endothermic peak at 173 ⁇ 5 ° C.
- the co-crystal represented by the formula [3a] is a co-crystal showing an endothermic peak of 173 ⁇ 3 ° C. by differential scanning calorimetry. More preferably, the co-crystal represented by the formula [3a] is a co-crystal showing an endothermic peak of 173 ⁇ 1 ° C. by differential scanning calorimetry.
- the temperature at which compound [3a] is dissolved in the crystallization solvent is, for example, 100 ° C. to 117 ° C., and preferably 110 ° C. ⁇ 5 ° C.
- the crystallization time is, for example, 15 hours to 48 hours, preferably 18 hours to 24 hours.
- the method for producing a co-crystal according to the present invention, or a compound according to the present invention or a salt thereof, or a solvate thereof can have, for example, the following advantages compared to Production Example 6 of Patent Document 1: (1) By using a highly stable co-crystal that can be isolated directly from the reaction mixture, it is possible to eliminate the steps of isolation and purification by silica gel column chromatography. Compound A (compound [4]) having a high molecular weight can be produced.
- the present invention includes the following specific embodiments: Item 1: 3-[(3S, 4R) -3-Methyl-6- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1,6-diazaspiro [3.4] octane-1- Yl] -3-oxopropanenitrile and 3,5-dimethylpyrazole.
- Item 3 The co-crystal according to Item 2, wherein m is 0.5.
- Item 4 The co-crystal according to any one of Items 1 to 3, wherein an extrapolation start temperature is 172 ⁇ 5 ° C. by differential scanning calorimetry.
- Item 5 At least one diffraction angle (2 ⁇ ) measured using CuK ⁇ radiation is 4.6 ° ⁇ 0.2 °, 18.6 ° ⁇ 0.2 °, or 20.9 ° ⁇ 0.2 °.
- Item 5 The co-crystal according to any one of Items 1 to 4, which exhibits a powder X-ray diffraction pattern having a peak.
- Item 6 The diffraction angles (2 ⁇ ) measured using CuK ⁇ radiation are 4.6 ° ⁇ 0.2 °, 12.6 ° ⁇ 0.2 °, 16.1 ° ⁇ 0.2 °, 18.6.
- Item 5 The co-crystal according to any one of Items 1 to 4, which exhibits a powder X-ray diffraction pattern having at least one peak at ° ⁇ 0.2 ° or 20.9 ° ⁇ 0.2 °.
- Item 7 Using the co-crystal according to any one of Items 1 to 6, the formula [4] Or a salt thereof.
- Term 8 Formula [1] Or a salt thereof and formula [2] Item 8.
- Item 9 Using the co-crystal according to any one of Items 1 to 6, the formula [4] Or a salt thereof.
- Term 10 Formula [1] Or a salt thereof and formula [2] Item 10.
- Term 11 Formula [3a] (In the formula, m is an arbitrary number from 0.4 to 0.5.) In which a co-crystal represented by formula [1] Or a salt thereof and formula [2] A method comprising a step of obtaining a co-crystal represented by the formula [3a] by reacting the compound of
- Term 12 Formula [3a] (In the formula, m is an arbitrary number from 0.4 to 0.5.) In which a co-crystal represented by the formula [4] Or a salt thereof and formula [5] A method comprising a step of obtaining a co-crystal represented by the formula [3a] by reacting the compound of
- Item 13 The method according to Item 11 or 12, wherein m is 0.5.
- Item 14 The method according to any one of Items 11 to 13, wherein the co-crystal represented by the formula [3a] is a co-crystal exhibiting an extrapolation start temperature of 172 ⁇ 5 ° C. by differential scanning calorimetry.
- Item 15 Powder X-ray diffraction in which the co-crystal represented by the formula [3a] uses CuK ⁇ radiation has a diffraction angle (2 ⁇ ) of 4.6 ° ⁇ 0.2 °, 18.6 ° ⁇ 0.2 °, or 20.
- Item 15 The method according to any one of Items 11 to 14, which is a co-crystal having at least one peak at 9 ° ⁇ 0.2 °.
- Item 16 The diffraction angle (2 ⁇ ) is 4.6 ° ⁇ 0.2 °, 12.6 ° ⁇ 0.2 °, or 16.2 in powder X-ray diffraction in which the co-crystal represented by the formula [3a] uses CuK ⁇ radiation.
- Item 15 The co-crystal according to any one of Items 11 to 14, which is a co-crystal having at least one peak at 1 ° ⁇ 0.2 °, 18.6 ° ⁇ 0.2 °, or 20.9 ° ⁇ 0.2 °. the method of.
- Item 17 Formula [4] produced by or capable of being produced by the method according to Item 7 or 8 Or a salt thereof.
- Item 18 Formula [3a] produced by or capable of being produced by the method according to Item 11 or 12 (In the formula, m is an arbitrary number from 0.4 to 0.5.) A co-crystal represented by
- Item 19 The co-crystal according to Item 18, wherein m is 0.5.
- SR-MDOP 4-[(3S, 4R) -3-methyl-1,6-diazaspiro [3.4] -octane-6-yl] -7H-pyrrolo [2,3-d] pyrimidine compound A (compound [4]): 3-[(3S, 4R) -3-Methyl-6- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1,6-diazaspiro [3.4] octane- 1-yl] -3-oxopropanenitrile
- S-BAPO (S) -2- (benzylamino) propan-1-ol
- S-BBMO (S) -N-benzyl-N- (1-hydroxypropane-2 -Yl) tert-butyl glycinate
- R-BCAB (R) -N-benzyl-N- (2-chloroprop
- the measurement apparatus and measurement conditions used in this example are shown below.
- the X-ray diffraction pattern of the sample was measured by a powder X-ray diffraction method.
- Measuring instrument X'Pert Pro (Spectris) Measurement conditions: Cathode: Copper Tube current and tube voltage of X-ray tube: 45 kV, 40 mA Sample rotation speed: 1 second each time Solar slit on the incident side: 0.02 rad Incident-side vertical divergence slit: 15 mm Divergence slit on the incident side: Automatic, irradiation width 15 mm Incident side scattering slit: 1 °
- Light-receiving side filter Nickel filter
- Light-receiving side solar slit 0.02 rad Divergence slit on the light receiving side: Automatic, irradiation width 15 mm
- Detector X'Celerator Detector mode: Scanning Detector effective width: 2.122 ° Scanning axis: Gonio Scanning mode: Continuous Scanning range: 3
- Elemental analysis determined the weight percent of carbon, hydrogen and nitrogen in the sample.
- the average value of the three measurement values of the sample solution was defined as the ion content in the sample.
- Measuring instrument Ion chromatograph LC-20 system (Shimadzu Corporation) Measurement conditions: Electric conductivity detector SHIMADZU CDD-10A VP Anion analysis column SHIMADZU SHIM-PAC IC-A3 Cation analysis column SHIMADZU SHIM-PAC IC-C1
- the water content in the sample was measured by the Karl Fischer method.
- Measuring instrument Coulometric titration moisture measuring device CA-06 (Mitsubishi Chemical Corporation) Measurement conditions: Sample amount: about 20 mg
- Reagent Anolyte Aquamicron AX (AP Corporation)
- a diffraction angle 2 ⁇ and a diffraction intensity of the synthesized compound A (compound [4]) and 3,5-dimethylpyrazole co-crystal (molar ratio 2: 1) were measured by a powder X-ray diffraction method.
- the obtained spectrum is shown in FIG.
- Each peak in FIG. 2 is as shown in the following table.
- a co-crystal of Compound A (Compound [4]) synthesized in Example 1 with 3,5-dimethylpyrazole (molar ratio 2: 1) (Compound [3-1]) (80 mg) was added at 65 ° C.
- the mixture was stirred at 65 ° C. for 2 hours and then stirred under ice cooling for 2 hours.
- the precipitated solid was collected by filtration, and the obtained solid was washed with ice-cooled acetonitrile (2.4 L).
- the obtained wet solid was dried under reduced pressure to co-crystal compound A (compound [4]) with 3,5-dimethylpyrazole (molar ratio 2: 1) (compound [3-1]) ( 1070 g, 2.99 mol) was obtained with a yield of 90.8%.
- a diffraction angle 2 ⁇ and a diffraction intensity of the synthesized compound A (compound [4]) and 3,5-dimethylpyrazole co-crystal (molar ratio 2: 1) were measured by a powder X-ray diffraction method.
- the obtained spectrum is shown in FIG.
- Each peak in FIG. 4 is as shown in the following table.
- the obtained organic layer was washed with water (175 mL), then the aqueous layer was discharged, and the solvent of the organic layer was distilled off under reduced pressure.
- the operation of adding toluene (105 mL) to the concentrated residue and concentrating was repeated three times, and a toluene solution of S-BBMO [8] (74.0 g, corresponding to 212 mmol) was obtained.
- the obtained toluene solution of S-BBMO was used in the next step with a yield of 100%.
- the crude S-BBMO product synthesized by the same method was concentrated to dryness, and NMR and MS were measured.
- the obtained organic layer was washed successively with aqueous citric acid (25 mL), aqueous sodium bicarbonate (25 mL) and water (25 mL), and then the solvent of the organic layer was distilled off under reduced pressure.
- the operation of adding acetonitrile (15 mL) to this concentrated residue and concentrating again was repeated three times.
- Acetonitrile (15 mL) and activated carbon (0.25 g) were added to the concentrated residue, and the mixture was stirred at room temperature for 2 hours. The activated carbon was removed by filtration, and the reaction vessel and the filtration residue were washed with acetonitrile (10 mL).
- Example 8 Production of RS-ZMAA-DN ⁇ 2H 2 O (Compound [14]) Under a nitrogen atmosphere, acetonitrile (15 mL) was added to an acetonitrile solution of RS-ZMBB [13] (13.2 g, corresponding to 16.8 mmol) at room temperature. To this solution, p-toluenesulfonic acid monohydrate (6.4 g, 33.6 mmol) was added at room temperature. The reaction mixture was stirred at 50 ° C. for 12 hours, cooled to room temperature, and water (7.5 mL) was added dropwise.
- the reaction mixture was stirred at room temperature for 2 hours, and then toluene (50 mL) was added and further stirred.
- the organic layer was separated.
- the obtained organic layer was washed once with 20 mL of 10% brine, three times with a mixed solution of 5% aqueous sodium bicarbonate (20 mL) and 10% brine (20 mL), 5% aqueous potassium hydrogen sulfate solution (10 mL) and 10% brine.
- the mixture was washed successively with a mixed solution of water (10 mL) once and twice with 10% brine (20 mL).
- the dropping funnel was washed with toluene (1.8 mL), and the washing solution was combined with the reaction mixture.
- the reaction mixture was stirred at 0 ° C. to 10 ° C. for about 2 hours, and water (28 mL) was added dropwise at 0 ° C. to 20 ° C.
- the reaction mixture was stirred at 0 ° C. to 20 ° C. for about 30 minutes, and then the organic layer was separated. The obtained organic layer was washed twice with 10% brine (18 mL).
- Example 12 Production of SR-ZMDB (Compound [18]) Under a nitrogen atmosphere, toluene (55 mL) was added to a toluene solution of RS-ZMSS [17] (corresponding to 23.7 mmol), benzylamine (17.8 g) was added dropwise at room temperature, and the dropping funnel was added with toluene (9.2 mL). Wash and add wash to reaction mixture. The reaction mixture was stirred at room temperature for about 1 hour, from 55 ° C. to 65 ° C. for about 3 hours, and then from 70 ° C. to 80 ° C. for about 6 hours.
- Example 13 Production of SR-MDOZ (Compound [19]) Under a nitrogen atmosphere, a toluene solution (corresponding to 23.7 mmol) of SR-ZMDB [18] was added dropwise to a solution of 1-chloroethyl chloroformate (3.72 g) and toluene (28 mL) at 0 to 10 ° C., and a dropping funnel was added. Wash with toluene (4.6 mL) and add the wash to the reaction mixture. Triethylamine (718 mg) was added to the reaction mixture at 0 ° C. to 10 ° C., and the mixture was stirred at 15 ° C. to 25 ° C. for about 2 hours. Stir.
- the organic layer was separated from the reaction mixture, and the obtained organic layer was washed twice with 20% brine (18 mL), and then the solvent of the organic layer was distilled off under reduced pressure.
- SR-MDOZ synthesized by the same method was concentrated to dryness, and NMR and MS were measured.
- Example 14 Production of SR-MDOZ-OX (Compound [20]) Under a nitrogen atmosphere, oxalic acid (761 mg) was dissolved in tetrahydrofuran (40 mL), and a tetrahydrofuran solution (corresponding to 3.84 mmol) of SR-MDOZ [19] was added dropwise at room temperature. To this solution, SR-MDOZ-OX crystals (1 mg) prepared in advance in the same manner as this method were added at room temperature, followed by stirring at room temperature for about 3.5 hours to precipitate crystals.
- the obtained organic layer was washed with 20% aqueous potassium carbonate solution (48 mL), and further washed twice with water (48 mL). Subsequently, the solvent of the organic layer was distilled off under reduced pressure. The operation of adding tert-butanol (60 mL) to the concentrated residue and concentrating was repeated three times. Tert-butanol (36 mL) was added to the concentrated residue to obtain a tert-butanol solution (61.1 g, corresponding to 34.2 mmol) of SR-MDPZ [21]. The obtained tert-butanol solution of SR-MDPZ was used in the next step with a yield of 100%.
- reaction vessel and insoluble material were washed with tert-butanol (24 mL), and 8M aqueous sodium hydroxide solution (25.7 mL, 205 mmol) and sodium chloride (13.2 g) were added to the washing solution and the filtrate.
- the reaction mixture was stirred at 50 ° C. for 2 hours, toluene (84 mL) was added at room temperature, and the organic layer was separated. The obtained organic layer was washed with 20% brine (60 mL), then anhydrous sodium sulfate was added and stirred, and then sodium sulfate was filtered.
- Toluene (60 mL) was added to the concentrated residue, and the mixture was stirred at 50 ° C. for 2 hours, and then the solvent was distilled off under reduced pressure.
- Toluene (60 mL) was again added to the concentrated residue and concentrated.
- Toluene (48 mL) was added to the concentrated residue, and the mixture was stirred at room temperature for 1 hour and then under ice cooling for 1 hour.
- Example 17 X-ray structural analysis of single crystal Compound A (compound [4]) co-crystal with 3,5-dimethylpyrazole (molar ratio 2: 1) (compound [3-1]) single crystal was prepared. Then, X-ray structural analysis was performed. (Single crystal preparation method) Acetonitrile (1 mL) was added to Compound A (Compound [4]) co-crystal with 3,5-dimethylpyrazole (molar ratio 2: 1) (10 mg) and heated at 70 ° C. for 2 hours. The resulting solution was filtered through a membrane filter (PTFE, 13 mm ⁇ ). The filtrate was allowed to stand at room temperature for 4 days to obtain a single crystal.
- PTFE membrane filter
- X-ray diffraction data was acquired at the beam line BL2S1 (radiation facility: Aichi Synchrotron Light Center). (Measurement condition) Wavelength: 0.74998mm Beam size: 100 ⁇ m ⁇ Camera length: 90 mm Offset: 70 mm (vertical direction) Vibration angle: 2 ° Measuring range: 180 ° Measurement temperature: 100K (-173.15 °C) The results of analysis with the following data analysis program are shown in the following table.
- FIG. 5 shows an ORTEP diagram of the cocrystal (molar ratio 2: 1) of the obtained compound A (compound [4]) with 3,5-dimethylpyrazole.
- a co-crystal for example, Compound [3a] of Compound A (Compound [4]) and 3,5-dimethylpyrazole according to the present invention is useful for the production of Compound A (Compound [4]).
- the present invention provides a method for stably producing the co-crystal with good chemical purity.
- the present invention also provides a method for stably producing Compound A (Compound [4]) with good chemical purity.
- the production method according to the present invention is useful as an industrial mass synthesis method because the co-crystal can be directly isolated from the reaction mixture.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
Description
3-[(3S,4R)-3-メチル-6-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-1,6-ジアザスピロ[3.4]オクタン-1-イル]-3-オキソプロパンニトリルと3,5-ジメチルピラゾールとの共結晶。
(1)反応混合物から、式[4]の化合物を共結晶(例えば、化合物[3a])として単離すること;又は
(2)反応混合物に、予め製造した共結晶(例えば、化合物[3a])を種晶として添加した後、当該反応混合物から、式[4]の化合物を共結晶(例えば、化合物[3a])として単離すること。
式[4]の化合物又はその塩を製造する方法において、上記(1)又は(2)で単離した共結晶(例えば、化合物[3a])から、式[4]の化合物又はその塩を得ることができる。
(1)反応混合物から、式[4]の化合物を共結晶(例えば、化合物[3a])として単離すること;
(2)式[4]の化合物又はその塩の粗生成物を共結晶(例えば、化合物[3a])に変換した後、式[4]の化合物を共結晶(例えば、化合物[3a])として単離すること;
(3)反応混合物に、予め製造した共結晶(例えば、化合物[3a])を種晶として添加した後、当該反応混合物から、式[4]の化合物を共結晶(例えば、化合物[3a])として単離すること;又は
(4)式[4]の化合物又はその塩の粗生成物を、予め製造した共結晶(例えば、化合物[3a])を種晶として添加して、共結晶(例えば、化合物[3a])に変換した後、式[4]の化合物を共結晶(例えば、化合物[3a])として単離すること。
式[4]の化合物又はその塩を精製する方法において、上記(1)~(4)のいずれかで単離した共結晶(例えば、化合物[3a])を溶解後、結晶化を含むステップを経由して、精製された式[4]の化合物又はその塩を得ることができる。
無機酸としては、例えば塩酸、硝酸、硫酸、リン酸、臭化水素酸等が挙げられる。
有機酸としては、例えばシュウ酸、マロン酸、マレイン酸、クエン酸、フマル酸、テレフタル酸、乳酸、リンゴ酸、コハク酸、酒石酸、酢酸、トリフルオロ酢酸、グルコン酸、アスコルビン酸、メタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、10-カンファースルホン酸等が挙げられる。
無機塩基との塩としては、例えばナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩等が挙げられる。
有機塩基としては、例えばメチルアミン、ジエチルアミン、トリメチルアミン、トリエチルアミン、エタノールアミン、ジエタノールアミン、トリエタノールアミン、エチレンジアミン、トリス(ヒドロキシメチル)メチルアミン、ジシクロヘキシルアミン、N,N-ジベンジルエチレンジアミン、グアニジン、ピリジン、ピコリン、コリン、シンコニン、メグルミン等が挙げられる。
アミノ酸としては、例えばリジン、アルギニン、アスパラギン酸、グルタミン酸等が挙げられる。
溶媒和物とは、本発明に係る化合物又はその塩に、溶媒の分子が配位したものであり、水和物も包含される。溶媒和物は、製薬上許容される溶媒和物が好ましく、例えば本発明に係る化合物又はその塩の水和物、エタノール和物、DMSO和物、1-プロパノール和物、2-プロパノール和物、クロロホルム和物、ジオキサン和物、アニソール和物、アセトン和物、エチレングリコール和物、ジメチルアセトアミド和物等が挙げられる。
本発明に係る化合物は、炭素-炭素二重結合を有する場合がある。その場合、本発明に係る化合物は、E体、Z体、又はE体とZ体の混合物として存在し得る。
本発明に係る化合物は、シス/トランス異性体として認識すべき立体異性体として存在する場合がある。その場合、本発明に係る化合物は、シス体、トランス体、又はシス体とトランス体の混合物として存在し得る。
本発明に係る化合物は、1又はそれ以上の不斉炭素原子を有する場合がある。その場合、本発明に係る化合物は、単一のエナンチオマー、単一のジアステレオマー、エナンチオマーの混合物又はジアステレオマーの混合物として存在する場合がある。
本発明に係る化合物は、アトロプ異性体として存在する場合がある。その場合、本発明に係る化合物は、個々のアトロプ異性体又は異なるアトロプ異性体の混合物として存在し得る。
本発明に係る化合物は、上記の異性体を生じさせる構造上の特徴を同時に複数含み得る。また、本発明に係る化合物は、上記の異性体をあらゆる比率で含み得る。
例えば、エナンチオマー混合物と、実質的に純粋なエナンチオマーであってキラル補助剤(chiral auxiliary)として知られている化合物とを反応させて形成させたジアステレオマー混合物から、分別結晶化やクロマトグラフィーのような標準的な方法により、異性体比率を高めた又は実質的に純粋な単一のジアステレオマーを分離することができる。この分離されたジアステレオマーを、付加されたキラル補助剤を開裂反応にて除去することにより、目的のエナンチオマーに変換することができる。
また、当分野でよく知られた、キラル固定相を使用するクロマトグラフィー法によって、エナンチオマー混合物を直接分離して目的のエナンチオマーを得ることもできる。
あるいは、目的のエナンチオマーを、実質的に純粋な光学活性出発原料を用いることにより、又は、プロキラル(prochiral)な合成中間体に対しキラル補助剤や不斉触媒を用いた立体選択的合成(すなわち、不斉誘導)を行うことによっても得ることができる。
で示される共結晶は、好ましくは、mが0.5である共結晶である。
別の好ましい態様において、式[3a]で示される共結晶は、mが0.40~0.48、0.40~0.46、0.40~0.44、0.40~0.42、0.42~0.50、0.44~0.50、0.46~0.50、0.48~0.50、0.42~0.44、0.44~0.46又は0.46~0.48である共結晶である。
各工程において、反応は溶媒中で行ってもよい。
各工程で得られる化合物は、必要に応じて、蒸留、再結晶、カラムクロマトグラフィー等の公知の方法で単離及び精製することができるが、場合によっては、単離又は精製せず次の工程に進むことができる。
本明細書において、室温とは温度を制御していない状態を示し、一つの態様として1℃から40℃を意味する。反応温度は、記載された温度±5℃、好ましくは±2℃を含むことができる。
式[3a]に示される共結晶は、式[1]の化合物と1-シアノアセチル-3,5-ジメチル-1H-ピラゾール(DPCN)[2]を縮合させることにより製造することができる。式[1]の化合物は、その塩であってもよく、フリー体から塩、塩からフリー体の形成は、公知の方法に従って行えばよい。
好ましい溶媒はアセトニトリルである。
DPCN[2]は、例えば式[1]の化合物に対して0.95当量から1.2当量用いることができ、好ましくは1.1当量±0.05当量である。別の好ましい態様は1.0当量±0.05当量である。
反応温度は、例えば室温から80℃であり、好ましくは70℃から80℃である。
反応時間は、例えば0.5時間から12時間であり、好ましくは0.5時間から6時間である。
式[3a]に示される共結晶のmは、反応条件、当該共結晶の濾取条件又は乾燥条件により、0.4~0.5の任意の数字になり得る。
好ましくは、式[3a]に示される共結晶は、CuKα放射を使用して測定した回折角(2θ)が4.6°±0.1°、18.6°±0.1°又は20.9°±0.1°に少なくとも一個(例えば、少なくとも1、2または3個)のピークを有する粉末X線回折パターンを示す結晶である。
より好ましくは、式[3a]に示される共結晶は、CuKα放射を使用して測定した回折角(2θ)が4.6°±0.06°、18.6°±0.06°又は20.9°±0.06°に少なくとも一個(例えば、少なくとも1、2または3個)のピークを有する粉末X線回折パターンを示す結晶である。
さらに、式[3a]に示される共結晶は、例えばCuKα放射を使用して測定した回折角(2θ)が4.6°±0.2°、12.6°±0.2°、16.1°±0.2°、18.6°±0.2°又は20.9°±0.2°に少なくとも一個(例えば、少なくとも1、2、3、4または5個)のピークを有する粉末X線回折パターンを示す結晶である。
好ましくは、式[3a]に示される共結晶は、CuKα放射を使用して測定した回折角(2θ)が4.6°±0.1°、12.6°±0.1°、16.1°±0.1°、18.6°±0.1°又は20.9°±0.1°に少なくとも一個(例えば、少なくとも1、2、3、4または5個)のピークを有する粉末X線回折パターンを示す結晶である。
より好ましくは、式[3a]に示される共結晶は、CuKα放射を使用して測定した回折角(2θ)が4.6°±0.06°、12.6°±0.06°、16.1°±0.06°、18.6°±0.06°又は20.9°±0.06°に少なくとも一個(例えば、少なくとも1、2、3、4または5個)のピークを有する粉末X線回折パターンを示す結晶である。
好ましくは、式[3a]に示される共結晶は、示差走査熱量測定で172±3℃の補外開始温度を示す共結晶である。
より好ましくは、式[3a]に示される共結晶は、示差走査熱量測定で172±1℃の補外開始温度を示す共結晶である。
式[3a]に示される共結晶は、示差走査熱量測定で173±5℃の吸熱ピークを示す共結晶である。
好ましくは、式[3a]に示される共結晶は、示差走査熱量測定で173±3℃の吸熱ピークを示す共結晶である。
より好ましくは、式[3a]に示される共結晶は、示差走査熱量測定で173±1℃の吸熱ピークを示す共結晶である。
式[4]の化合物は、式[3a]の化合物を溶解後、結晶化させることにより製造(精製)することができる。結晶化の際に、2,6-ジ-tert-ブチル-4-メチルフェノール(BHT)を加えて、製造(精製)を実施してもよい。
結晶化溶媒としては、例えば1-ブタノール、1-プロパノールが例示される。好ましい溶媒は1-ブタノールである。溶媒は、例えば式[3a]の化合物の重量に対して8.0倍量から20倍量用いることができ、好ましくは8.5倍量±0.5倍量である。
化合物[3a]を結晶化溶媒に溶解させる温度は、例えば100℃から117℃であり、好ましくは110℃±5℃である。
結晶化時間は、例えば15時間から48時間であり、好ましくは18時間から24時間である。
(1)反応混合液から直接単離することのできる、安定性の高い共結晶を利用することにより、抽出及びシリカゲルカラムクロマトグラフィーによる単離精製工程を省くことが可能であり、さらに、化学純度の高い化合物A(化合物[4])の製造が可能であること。
項1: 3-[(3S,4R)-3-メチル-6-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-1,6-ジアザスピロ[3.4]オクタン-1-イル]-3-オキソプロパンニトリルと3,5-ジメチルピラゾールとの共結晶。
で示される共結晶を製造する方法であって、式[1]
で示される共結晶を製造する方法であって、式[4]
化合物A(化合物[4])の製造(精製)(実施例3)、化合物[6]の製造(実施例4工程4)及び化合物[20]の製造(実施例14)の結晶化過程において、結晶化促進のために、種晶を用いた。これらの化合物の結晶は、種晶を用いなくても、実施例に記載の方法に準じた方法で得ることができる。
SR-MDOP:4-[(3S,4R)-3-メチル-1,6-ジアザスピロ[3.4]-オクタン-6-イル]-7H-ピロロ[2,3-d]ピリミジン
化合物A(化合物[4]):3-[(3S,4R)-3-メチル-6-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-1,6-ジアザスピロ[3.4]オクタン-1-イル]-3-オキソプロパンニトリル
S-BAPO:(S)-2-(ベンジルアミノ)プロパン-1-オール
S-BBMO:(S)-N-ベンジル-N-(1-ヒドロキシプロパン-2-イル)グリシン酸tert-ブチル
R-BCAB:(R)-N-ベンジル-N-(2-クロロプロピル)グリシン酸tert-ブチル
S-MABB:(3S)-1-ベンジル-3-メチルアゼチジン-2-カルボン酸tert-ブチル
S-MABB-HC:(3S)-1-ベンジル-3-メチルアゼチジン-2-カルボン酸tert-ブチル塩酸塩
S-MACB-HC:(3S)-3-メチルアゼチジン-2-カルボン酸tert-ブチル塩酸塩
S-ZMAB:2-(tert-ブチル)(3S)-3-メチルアゼチジン-1,2-ジカルボン酸1-ベンジル
RS-ZMBB:2-(tert-ブチル)(2R,3S)-2-(2-(tert-ブトキシ)-2-オキソエチル)-3-メチルアゼチジン-1,2-ジカルボン酸1-ベンジル
RS-ZMAA:(2R,3S)-1-((ベンジルオキシ)カルボニル)-2-(カルボキシメチル)-3-メチルアゼチジン-2-カルボン酸
RS-ZMAA-DN・2H2O:(2R,3S)-1-((ベンジルオキシ)カルボニル)-2-(カルボキシメチル)-3-メチルアゼチジン-2-カルボン酸二ナトリウム塩二水和物
RS-ZMOO:(2R,3S)-2-(2-ヒドロキシエチル)-2-(ヒドロキシメチル)-3-メチルアゼチジン-1-カルボン酸ベンジル
RS-ZMSS:(2R,3S)-3-メチル-2-(2-((メチルスルホニル)オキシ)エチル)-2-(((メチルスルホニル)オキシ)メチル)アゼチジン-1-カルボン酸ベンジル
SR-ZMDB:(3S,4R)-6-ベンジル-3-メチル-1,6-ジアザスピロ[3.4]オクタン-1-カルボン酸ベンジル
SR-MDOZ:(3S,4R)-3-メチル-1,6-ジアザスピロ[3.4]オクタン-1-カルボン酸ベンジル
SR-MDOZ-OX:(3S,4R)-3-メチル-1,6-ジアザスピロ[3.4]オクタン-1-カルボン酸ベンジルシュウ酸塩
SR-MDPZ:ベンジル-(3S,4R)-3-メチル-6-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-1,6-ジアザスピロ[3.4]オクタン-1-カルボキシラート
BHT:2,6-ジ-tert-ブチル-4-メチルフェノール
DPCN:1-シアノアセチル-3,5-ジメチル-1H-ピラゾール
CPPY:4-クロロ-7H-ピロロ[2,3-d]ピリミジン
TBBA:ブロモ酢酸tert-ブチルエステル
PTFE:ポリテトラフルオロエチレン
実施例中の記号は次のような意味である。
s:シングレット(singlet)
d:ダブレット(doublet)
t:トリプレット(triplet)
q:カルテット(quartet)
dd:ダブルダブレット(double doublet)
dq:ダブルカルテット(double quartet)
ddd:ダブルダブルダブレット(double double doublet)
brs:ブロードシングレット(broad singlet)
m:マルチプレット(multiplet)
J:カップリング定数(coupling constant)
測定機器:X’Pert Pro(スペクトリス社)
測定条件:対陰極 :銅
X線管球の管電流と管電圧 :45kV、40mA
試料の回転速度 :毎回1秒
入射側のソーラースリット :0.02rad
入射側の縦発散スリット :15mm
入射側の発散スリット :自動、照射幅15mm
入射側の散乱スリット :1°
受光側のフィルタ :ニッケルフィルタ
受光側のソーラースリット :0.02rad
受光側の発散スリット :自動、照射幅15mm
検出器 :X’Celerator
検出器のモード :スキャニング
検出器の有効幅 :2.122°
走査軸 :ゴニオ
走査モード :連続
走査範囲 :3°から60°
単位ステップあたりの時間 :10秒
測定機器:イオンクロマトグラフLC-20システム(島津製作所社)
測定条件:電気伝導度検出器 SHIMADZU CDD-10A VP
陰イオン分析用カラム SHIMADZU SHIM-PAC IC-A3
陽イオン分析用カラム SHIMADZU SHIM-PAC IC-C1
測定機器:電量滴定式水分測定装置CA-06型(三菱化学株式会社)
測定条件:サンプル量:約20mg
試薬:陽極液 アクアミクロンAX(エーピーアイコーポレーション)
陰極液 アクアミクロンCXU(エーピーアイコーポレーション)
合成した化合物A(化合物[4])の3,5-ジメチルピラゾールとの共結晶(モル比2:1)のNMR、元素分析と示差走査熱量を測定した。
1H-NMR (DMSO-d6) δ: 11.98 (br s, 0.5H), 11.59 (br s, 1H), 8.08 (s, 1H), 7.11 (dd, 1H, J = 3.5, 2.2 Hz), 6.58 (dd, 1H, J = 3.5, 1.4 Hz), 5.73 (s, 0.5H), 4.16 (t, 1H, J = 8.3 Hz), 4.09-3.93 (m, 3H), 3.84-3.74 (m, 1H), 3.70 (d, 1H, J = 19.0 Hz), 3.65 (d, 1H, J = 19.0 Hz), 3.58 (dd, 1H, J = 8.2, 5.9 Hz), 2.70-2.58 (m, 2H), 2.22-2.12 (m, 1H), 2.12 (s, 3H), 1.12 (d, 3H, J = 7.2 Hz).
元素分析:C 61.9wt%, H 6.1wt%, N 27.2wt% (理論値 C 62.0wt%, H 6.2wt%, N 27.4wt%)
示差走査熱量測定:
示差走査熱量測定装置DSC-60A(島津製作所社製)を用いて、昇温速度5℃/分(アルミニウム製密閉パン)で測定した。測定により得られたDSC曲線を図1に示した。DSC曲線上の吸熱ピークのエンタルピーは、100.26J/gであり、吸熱温度は、173.66℃であり、補外開始温度は、172.36℃であった。得られたスペクトルを図1に示す。
図2の各ピークは以下の表のとおりである。
合成した化合物A(化合物[4])の3,5-ジメチルピラゾールとの共結晶(モル比2:1)のNMR、元素分析と示差走査熱量を測定した。
1H-NMR (DMSO-d6) δ: 11.99 (br s, 0.5H), 11.59 (br s, 1H), 8.11 (s, 1H), 7.11 (s, 1H), 6.58 (d, 1H, J = 3.0 Hz), 5.73 (s, 0.5H), 4.16 (t, 1H, J = 8.4 Hz), 4.10-3.92 (m, 3H), 3.85-3.74 (m, 1H), 3.70 (d, 1H, J = 19.1 Hz), 3.65 (d, 1H, J = 19.1 Hz), 3.57 (dd, 1H, J = 7.9, 6.1 Hz), 2.70-2.58 (m, 2H), 2.22-2.14 (m, 1H), 2.12 (s, 3H), 1.12 (d, 3H, J = 6.9 Hz).
元素分析:C 62.0wt%, H 6.2wt%, N 27.2wt% (理論値 C 62.0wt%, H 6.2wt%, N 27.4wt%)
示差走査熱量測定:
示差走査熱量測定装置DSC-60A(島津製作所社製)を用いて、昇温速度5℃/分(アルミニウム製密閉パン)で測定した。測定により得られたDSC曲線を図3に示した。DSC曲線上の吸熱ピークのエンタルピーは、78.02J/gであり、吸熱温度は、173.81℃であり、補外開始温度は、172.02℃であった。得られたスペクトルを図3に示す。
図4の各ピークは以下の表のとおりである。
同じ方法で合成した化合物A(化合物[4])のNMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 11.58 (br s, 1H), 8.08 (s, 1H), 7.11 (dd, 1H, J = 3.5, 2.3 Hz), 6.58 (dd, 1H, J = 3.5, 1.6 Hz), 4.16 (t, 1H, J = 8.4 Hz), 4.10-3.94 (m, 3H), 3.84-3.74 (m, 1H), 3.70 (d, 1H, J = 19.0 Hz), 3.65 (d, 1H, J = 18.7 Hz), 3.58 (dd, 1H, J = 8.2, 5.9 Hz), 2.70-2.59 (m, 2H), 2.23-2.12 (m, 1H), 1.12 (d, 3H, J = 7.2 Hz).
MS: m/z = 311 [M+H]+
同じ方法で合成したS-BBMO粗生成物を濃縮乾固し、NMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 7.36-7.13 (5H, m), 4.26 (1H, dd, J = 6.8, 3.9 Hz), 3.72 (2H, dd, J = 14.2, 6.8 Hz), 3.47-3.38 (1H, m), 3.30-3.08 (3H, m), 2.79 (1H, sext, J = 6.8 Hz), 1.35 (9H, s), 0.96 (3H, d, J = 6.8 Hz).
MS: m/z = 280 [M+H]+
同じ方法で合成したR-BCAB粗生成物を濃縮乾固し、NMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 7.28-7.11 (5H, m), 4.24-4.11 (1H, m), 3.80 (2H, d, J = 3.6 Hz), 3.24 (2H, d, J = 3.6 Hz), 2.98-2.78 (2H, m), 1.46-1.37 (12H, m).
MS: m/z = 298 [M+H]+
同じ方法で合成したS-MABB粗生成物を濃縮乾固し、NMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 7.28-7.25 (10H, m), 3.75 (1H, d, J = 12.7 Hz), 3.68 (1H, d, J = 1.4 Hz), 3.66 (1H, d, J = 6.7 Hz), 3.46 (2H, d, J = 12.7 Hz), 3.30-3.17 (2H, m), 2.95 (1H, dd, J = 6.2, 1.2 Hz), 2.77 (1H, dd, J = 6.1, 2.2 Hz), 2.65-2.55 (1H, m), 2.48-2.40 (2H, m), 1.35 (9H, s), 1.35 (9H, s), 1.12 (3H, d, J = 7.2 Hz), 1.09 (3H, d, J = 6.2 Hz).
MS: m/z = 262 [M+H]+
同じ方法で合成したS-MABB-HCのNMR、MS及びCl含量を測定した。
1H-NMR (DMSO-d6) δ: 11.08 (1H, br s), 10.94 (1H, br s), 7.52-7.42 (10H, m), 5.34 (1H, t, J = 8.4 Hz), 4.90 (1H, br s), 4.45-4.10 (5H, m), 3.92-3.49 (3H, br m), 3.10-2.73 (2H, br m), 1.35 (9H, s), 1.29 (9H, s), 1.24 (3H, d, J = 6.7 Hz), 1.17 (3H, d, J = 7.4 Hz).
MS: m/z = 262 [M+H-HCl]+
Cl含量(イオンクロマトグラフィー):11.9%(理論値:11.9%)
同じ方法で合成したS-MACB-HC粗生成物を濃縮乾固し、NMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 9.60 (br s, 1H), 4.97 (d, 1H, J = 9.2 Hz), 4.61 (d, 1H, J = 8.4 Hz), 4.01 (dd, 1H, J = 10.0, 8.4 Hz), 3.78-3.74 (m, 1H), 3.54 (dd, 1H, J = 9.6, 8.4 Hz), 3.35 (dd, 1H, J = 10.0, 6.0 Hz), 3.15-3.03 (m, 1H), 3.00-2.88 (m, 1H), 1.49 (s, 9H), 1.47 (s, 9H), 1.22 (d, 3H, J = 6.8 Hz), 1.14 (d, 3H, J = 7.2 Hz).
MS: m/z = 172 [M+H]+ (フリー体)
同じ方法で合成したS-ZMAB粗生成物を濃縮乾固し、NMRとMSを測定した。
1H-NMR (CDCl3) δ: 7.38-7.28 (m, 10H), 5.16-5.04 (m, 4H), 4.60 (d, 1H, J = 9.2 Hz), 4.18-4.12 (m, 2H), 4.04 (t, 1H, J = 8.6 Hz), 3.66 (dd, 1H, J = 7.6, 7.2 Hz), 3.50 (dd, 1H, J = 8.0, 5.2 Hz), 3.05-2.94 (m, 1H), 2.60-2.50 (m, 1H), 1.43 (br s, 18H), 1.33 (d, 3H, J = 6.5 Hz), 1.15 (d, 3H, J = 7.2 Hz).
MS: m/z = 328 [M+Na]+
同じ方法で合成したRS-ZMBB粗生成物を濃縮乾固し、NMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 7.38-7.29 (m, 5H), 5.09-4.96 (m, 2H), 3.91 (t, 0.4H, J = 8.0 Hz), 3.79 (t, 0.6H, J = 8.0 Hz), 3.55 (t, 0.4H, J = 7.2 Hz), 3.46 (t, 0.6H, J = 7.5 Hz), 3.14-3.04 (m, 1H), 2.83-2.72 (m, 2H), 1.38 (br s, 9H), 1.37 (br s, 3.6H), 1.34 (br s, 5.4H), 1.12-1.09 (m, 3H).
MS: m/z = 420 [M+H]+
同じ方法で合成したRS-ZMAA-DN・2H2OのNMR、MS、Na含量及び水分含量を測定した。
1H-NMR (DMSO-d6) δ: 7.32-7.22 (m, 5H), 4.97 (d, 1H, J = 12.7 Hz), 4.84 (d, 1H, J = 12.7 Hz), 3.79 (t, 1H, J = 8.0 Hz), 3.29 (d, 1H, J = 14.8 Hz), 3.16-3.12 (m, 1H), 2.17-2.09 (m, 2H), 1.07 (d, 3H, J = 6.9 Hz).
MS: m/z = 352 [M+H]+ (無水物)
Na含量(イオンクロマトグラフィー):13.3%(水分含量補正後)(理論値;13.1%)
水分含量(カール・フィッシャー法):9.8%(理論値;9.3%)
同じ方法で合成したRS-ZMAAを濃縮し、NMRとMSを測定した。
1H-NMR (DMSO-D6) δ: 7.35-7.28 (m, 5H), 5.06-4.94 (m, 2H), 3.86 (dt, 1H, J = 48.4, 7.9 Hz), 3.50 (dt, 1H, J = 37.9, 7.4 Hz), 3.16-3.02 (br m, 1H), 2.91-2.77 (br m, 2H), 1.08 (d, 3H, J = 6.9 Hz)
MS: m/z = 308 [M+H]+
同じ方法で合成したRS-ZMOOを濃縮し、NMRとMSを測定した。
1H-NMR (CDCl3) δ: 7.39-7.30 (m, 5H), 5.10 (s, 2H), 4.15-4.01 (br m, 2H), 3.83-3.73 (br m, 3H), 3.48 (dd, 1H, J = 8.3, 6.4 Hz), 2.59-2.50 (br m, 1H), 2.46-2.40 (br m, 1H), 2.07-1.99 (m, 1H), 1.14 (d, 3H, J = 7.2 Hz)
MS: m/z = 280 [M+H]+
同じ方法で合成したRS-ZMSSを濃縮乾固し、NMRとMSを測定した。
1H-NMR (DMSO-D6) δ: 7.37-7.27 (br m, 5H), 5.10-4.98 (m, 2H), 4.58-4.22 (br m, 4H), 3.84 (dt, 1H, J = 45.6, 8.1 Hz), 3.48-3.33 (br m, 1H), 3.17-3.10 (m, 6H), 2.81-2.74 (br m, 1H), 2.22-2.12 (m, 2H)
MS: m/z = 436 [M+H]+
1H-NMR (CDCl3) δ: 7.35-7.20 (m, 10H), 5.08 (d, 2H, J = 23.6 Hz), 3.94 (q, 1H, J = 7.9 Hz), 3.73-3.42 (br m, 2H), 3.30-3.23 (m, 1H), 3.05 (dd, 1H, J = 19.7, 9.5 Hz), 2.79 (dt, 1H, J = 69.6, 6.1 Hz), 2.57-2.32 (br m, 4H), 1.96-1.89 (m, 1H), 1.09 (d, 3H, J = 6.9 Hz)
MS: m/z = 351 [M+H]+
同じ方法で合成したSR-MDOZを濃縮乾固し、NMRとMSを測定した。
1H-NMR (CDCl3) δ: 7.37-7.28 (m, 5H), 5.08 (dd, 2H, J = 16.8, 12.8 Hz), 4.00 (dd, 1H, J = 17.1, 8.3 Hz), 3.40-3.31 (m, 1H), 3.24 (d, 1H, J = 12.7 Hz), 3.00 (dd, 1H, J = 54.9, 12.4 Hz), 2.87-2.57 (m, 3H), 2.47-2.27 (m, 1H), 1.91-1.80 (m, 1H), 1.14 (d, 3H, J = 7.2 Hz)
MS: m/z = 261 [M+H]+
同じ方法で合成したSR-MDOZ-OXのNMR、MS及び元素分析測定を行なった。
1H-NMR (DMSO-D6) δ: 7.37-7.30 (m, 5H), 5.15-5.01 (m, 2H), 3.92 (dt, 1H, J = 43.5, 8.4 Hz), 3.48-3.12 (br m, 5H), 2.67-2.56 (m, 1H), 2.46-2.35 (m, 1H), 2.12-2.05 (m, 1H), 1.13 (d, 3H, J = 6.9 Hz)
MS: m/z = 261 [M+H]+
元素分析:C 58.4wt%, H 6.4wt%, N 7.9%wt% (理論値 C 58.3wt%, H 6.3wt%, N 8.0wt%)
同じ方法で合成したSR-MDPZを酢酸エチルとn-ヘプタン混合溶媒により固体として取得し、NMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 11.59 (br s, 1H), 8.08 (s, 1H), 7.41-7.26 (br m, 3H), 7.22-7.08 (br m, 3H), 6.64-6.51 (br m, 1H), 5.07-4.91 (br m, 2H), 4.09-3.67 (br m, 5H), 3.47-3.32 (br m, 1H), 2.67-2.55 (br m, 2H), 2.21-2.15 (br m, 1H), 1.11 (d, 3H, J = 6.9 Hz).
MS: m/z = 378 [M+H]+
同じ方法で合成したSR-MDOPのNMRとMSを測定した。
1H-NMR (DMSO-d6) δ: 11.57 (br s, 1H), 8.07 (s, 1H), 7.10 (d, 1H, J = 3.2 Hz), 6.58 (d, 1H, J = 3.2 Hz), 3.92-3.59 (br m, 4H), 3.49 (dd, 1H, J = 8.3, 7.2 Hz), 2.93 (dd, 1H, J = 7.2, 6.1 Hz), 2.61-2.53 (m, 2H), 2.12-2.01 (br m, 2H), 1.10 (d, 3H, J = 6.9 Hz).
MS: m/z = 244 [M+H]+
化合物A(化合物[4])の3,5-ジメチルピラゾールとの共結晶(モル比2:1)(化合物[3-1])の単結晶を調製し、X線構造解析を実施した。
(単結晶調製法)
化合物A(化合物[4])の3,5-ジメチルピラゾールとの共結晶(モル比2:1)(10mg)にアセトニトリル(1mL)を加え、70℃にて2時間加熱した。得られた溶液をメンブランフィルター(PTFE,13mmφ)を通してろ過した。そのろ液を室温4日間静置することで単結晶を得た。
ビームラインBL2S1(放射光施設:あいちシンクトロン光センタ―)にて、X線回折データを取得した。
(測定条件)
波長:0.74998Å
ビームサイズ:100 μmφ
カメラ長:90 mm
オフセット:70 mm(垂直方向)
振動角:2°
測角範囲:180°
測定温度:100K(-173.15℃)
以下のデータ解析プログラムで解析した結果を以下の表に示す。
(データ解析プログラム)
データ測定、回折データ処理:XDS
結晶構造解析:SHELX97
構造精密化手法:Full-matrix least-squares on F2
化合物A(化合物[4])と3,5-ジメチルピラゾール間の水素結合により、得られた単結晶が共結晶であることが確認された。得られた化合物A(化合物[4])の3,5-ジメチルピラゾールとの共結晶(モル比2:1)のORTEP図を図5に示す。
Claims (16)
- 3-[(3S,4R)-3-メチル-6-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-1,6-ジアザスピロ[3.4]オクタン-1-イル]-3-オキソプロパンニトリルと3,5-ジメチルピラゾールとの共結晶。
- mが0.5である、請求項2に記載の共結晶。
- 示差走査熱量測定で補外開始温度が172±5℃である、請求項1から3のいずれか一項に記載の共結晶。
- CuKα放射を使用して測定した回折角(2θ)が4.6°±0.2°、18.6°±0.2°又は20.9°±0.2°に少なくとも一個のピークを有する粉末X線回折パターンを示す、請求項1から4のいずれか一項に記載の共結晶。
- CuKα放射を使用して測定した回折角(2θ)が4.6°±0.2°、12.6°±0.2°、16.1°±0.2°、18.6°±0.2°又は20.9°±0.2°に少なくとも一個のピークを有する粉末X線回折パターンを示す、請求項1から4のいずれか一項に記載の共結晶。
- mが0.5である、請求項11又は12に記載の方法。
- 式[3a]で示される共結晶が示差走査熱量測定で172±5℃の補外開始温度を示す共結晶である、請求項11から13のいずれか一項に記載の方法。
- 式[3a]で示される共結晶がCuKα放射を使用する粉末X線回折で回折角(2θ)4.6°±0.2°、18.6°±0.2°又は20.9°±0.2°に少なくとも一個のピークを有する共結晶である、請求項11から14のいずれか一項に記載の方法。
- 式[3a]で示される共結晶がCuKα放射を使用する粉末X線回折で回折角(2θ)4.6°±0.2°、12.6°±0.2°、16.1°±0.2°、18.6°±0.2°又は20.9°±0.2°に少なくとも一個のピークを有する共結晶である、請求項11から14のいずれか一項に記載の方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017384316A AU2017384316B2 (en) | 2016-12-21 | 2017-12-20 | Method for producing 7H-pyrrolo[2,3-d]pyrimidine derivative, and cocrystal of said derivative |
KR1020197016801A KR20190092433A (ko) | 2016-12-21 | 2017-12-20 | 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 공결정 |
US16/470,843 US11312728B2 (en) | 2016-12-21 | 2017-12-20 | Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof |
MX2019007452A MX2019007452A (es) | 2016-12-21 | 2017-12-20 | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. |
CN201780079190.2A CN110099910B (zh) | 2016-12-21 | 2017-12-20 | 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其共晶 |
CA3044796A CA3044796A1 (en) | 2016-12-21 | 2017-12-20 | Method for preparing 7h-pyrrolo[2,3-d]pyrimidine derivatives andd co-cryco-crystals thereof |
RU2019122565A RU2779212C2 (ru) | 2016-12-21 | 2017-12-20 | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНА И ИХ СОКРИСТАЛЛОВ |
JP2018511785A JP6359791B1 (ja) | 2016-12-21 | 2017-12-20 | 7H−ピロロ[2,3−d]ピリミジン誘導体の製造方法及びその共結晶 |
EP17883651.6A EP3560931A4 (en) | 2016-12-21 | 2017-12-20 | METHOD FOR PRODUCING A 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE, AND CO-CRYSTAL OF SAID DERIVATIVE |
BR112019012267A BR112019012267A2 (pt) | 2016-12-21 | 2017-12-20 | processo para a preparação do derivado de 7h-pirrolo [2,3-d]pirimidina e cocristais do mesmo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-247606 | 2016-12-21 | ||
JP2016247606 | 2016-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018117151A1 true WO2018117151A1 (ja) | 2018-06-28 |
Family
ID=62627695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/045728 WO2018117151A1 (ja) | 2016-12-21 | 2017-12-20 | 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその共結晶 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11312728B2 (ja) |
EP (1) | EP3560931A4 (ja) |
JP (1) | JP6359791B1 (ja) |
KR (1) | KR20190092433A (ja) |
CN (1) | CN110099910B (ja) |
AU (1) | AU2017384316B2 (ja) |
BR (1) | BR112019012267A2 (ja) |
CA (1) | CA3044796A1 (ja) |
MX (1) | MX2019007452A (ja) |
TW (1) | TWI790218B (ja) |
WO (1) | WO2018117151A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021025129A1 (ja) | 2019-08-07 | 2021-02-11 | ロート製薬株式会社 | 涙液分泌促進用眼科組成物 |
WO2021132598A1 (ja) | 2019-12-27 | 2021-07-01 | ロート製薬株式会社 | 水性組成物 |
WO2022025279A1 (ja) | 2020-07-30 | 2022-02-03 | ロート製薬株式会社 | 水性組成物 |
WO2022025281A1 (ja) | 2020-07-30 | 2022-02-03 | ロート製薬株式会社 | 水性組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011013785A1 (ja) | 2009-07-31 | 2011-02-03 | 日本たばこ産業株式会社 | 含窒素スピロ環化合物及びその医薬用途 |
WO2017006968A1 (ja) * | 2015-07-07 | 2017-01-12 | 日本たばこ産業株式会社 | 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその中間体 |
-
2017
- 2017-12-20 US US16/470,843 patent/US11312728B2/en active Active
- 2017-12-20 CN CN201780079190.2A patent/CN110099910B/zh active Active
- 2017-12-20 WO PCT/JP2017/045728 patent/WO2018117151A1/ja unknown
- 2017-12-20 TW TW106144829A patent/TWI790218B/zh active
- 2017-12-20 BR BR112019012267A patent/BR112019012267A2/pt active Search and Examination
- 2017-12-20 JP JP2018511785A patent/JP6359791B1/ja active Active
- 2017-12-20 MX MX2019007452A patent/MX2019007452A/es unknown
- 2017-12-20 KR KR1020197016801A patent/KR20190092433A/ko not_active Application Discontinuation
- 2017-12-20 EP EP17883651.6A patent/EP3560931A4/en active Pending
- 2017-12-20 AU AU2017384316A patent/AU2017384316B2/en active Active
- 2017-12-20 CA CA3044796A patent/CA3044796A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011013785A1 (ja) | 2009-07-31 | 2011-02-03 | 日本たばこ産業株式会社 | 含窒素スピロ環化合物及びその医薬用途 |
WO2017006968A1 (ja) * | 2015-07-07 | 2017-01-12 | 日本たばこ産業株式会社 | 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその中間体 |
Non-Patent Citations (2)
Title |
---|
CONCEPCIÓN LÓPEZ, ROSA M. CLARAMUNT, MARÍA ÁNGELES GARCÍA, ELENA PINILLA, M. ROSARIO TORRES, IBON ALKORTA, JOSÉ ELGUERO: "Cocrystals of 3,5-Dimethyl-1 H -pyrazole and Salicylic Acid: Controlled Formation of Trimers via O−H···N Hydrogen Bonds †", CRYSTAL GROWTH & DESIGN., vol. 7, no. 6, June 2007 (2007-06-01), pages 1176 - 1184, XP055587853, ISSN: 1528-7483, DOI: :10.1021/cg0701527 * |
See also references of EP3560931A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021025129A1 (ja) | 2019-08-07 | 2021-02-11 | ロート製薬株式会社 | 涙液分泌促進用眼科組成物 |
WO2021132598A1 (ja) | 2019-12-27 | 2021-07-01 | ロート製薬株式会社 | 水性組成物 |
WO2022025279A1 (ja) | 2020-07-30 | 2022-02-03 | ロート製薬株式会社 | 水性組成物 |
WO2022025281A1 (ja) | 2020-07-30 | 2022-02-03 | ロート製薬株式会社 | 水性組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP6359791B1 (ja) | 2018-07-18 |
JPWO2018117151A1 (ja) | 2018-12-20 |
EP3560931A4 (en) | 2020-05-13 |
RU2019122565A3 (ja) | 2021-04-21 |
MX2019007452A (es) | 2019-08-29 |
BR112019012267A2 (pt) | 2019-12-03 |
AU2017384316A1 (en) | 2019-05-09 |
EP3560931A1 (en) | 2019-10-30 |
TW201829421A (zh) | 2018-08-16 |
KR20190092433A (ko) | 2019-08-07 |
CN110099910A (zh) | 2019-08-06 |
US11312728B2 (en) | 2022-04-26 |
RU2019122565A (ru) | 2021-01-27 |
CA3044796A1 (en) | 2018-06-28 |
CN110099910B (zh) | 2022-12-20 |
US20200165269A1 (en) | 2020-05-28 |
TWI790218B (zh) | 2023-01-21 |
AU2017384316B2 (en) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6359791B1 (ja) | 7H−ピロロ[2,3−d]ピリミジン誘導体の製造方法及びその共結晶 | |
JP6871856B2 (ja) | 7H−ピロロ[2,3−d]ピリミジン誘導体の製造方法及びその中間体 | |
JP6434678B2 (ja) | 7H−ピロロ[2,3−d]ピリミジン誘導体の製造方法及びその合成中間体 | |
RU2779212C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНА И ИХ СОКРИСТАЛЛОВ | |
RU2776802C2 (ru) | Способ получения производных 7h-пирроло[2,3-d]пиримидина и промежуточных продуктов для их синтеза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018511785 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17883651 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017384316 Country of ref document: AU Date of ref document: 20171220 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3044796 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20197016801 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019012267 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017883651 Country of ref document: EP Effective date: 20190722 |
|
ENP | Entry into the national phase |
Ref document number: 112019012267 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190614 |